secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001654954-23-010489
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata reports Q2 2023 cash $8.4M; FDA agrees Phase 3 design for DMT310 acne
-----------------------------------------------------------------------------

- Cash $8.4M at June 30, 2023 vs $6.2M at Dec 31, 2022; net $5.7M from two 2023 financings.
- FDA agreed Phase 3 program acceptable for NDA; co-primary endpoints acceptable.
- Phase 3 STAR-1 study for DMT310 acne expected to start enrollment in 2H 2023.
- R&D expenses $0.8M Q2 2023 vs $1.6M Q2 2022; G&A $0.9M vs $1.1M.
- Cash resources expected to fund operations into Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423010489/0001654954-23-010489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423010489/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer